UPDATE: Morgan Stanley Reiterates On Mindray Medical International Ltd. On In-Line 1Q14 Sales Growth
In a report published Tuesday, Morgan Stanley analyst Bin Li reiterated an Equal-Weight rating on Mindray Medical International Ltd. (NYSE: MR), but removed the $37.00 price target.
In the report, Morgan Stanley noted, “MR reported in-line 1Q14 sales growth on continued weak China business but stabilized ex-China growth, while non-GAAP profit was also in line. Notably, operating income was 13% below our estimate, but helped by the lower tax rate. Given the challenging China environment and the departure of the COO, Mr. Liu Jie, who has been instrumental to Mindray's healthy growth in the past few years, we do not expect improving profit growth in the near term.”
Mindray Medical International Ltd. closed on Monday at $33.67.
Latest Ratings for MR
|Nov 2015||Standpoint Research||Downgrades||Buy||Hold|
|Jun 2015||JMP Securities||Upgrades||Underperform||Market Perform|
|Mar 2015||Credit Suisse||Downgrades||Neutral||Underperform|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.